Christoph Wanner

Research interests

Publications

• Chronic kidney disease and the global public health agenda: an international consensus

  Nature Reviews Nephrology · 2024 · https://doi.org/10.1038/s41581-024-00820-6

• 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension

  European Journal of Internal Medicine · 2024 · https://doi.org/10.1016/j.ejim.2024.05.033

• 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

  Journal of Hypertension · 2023 · https://doi.org/10.1097/hjh.0000000000003480

• Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association

  Cardiovascular Research · 2023 · https://doi.org/10.1093/cvr/cvad083

• KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

  Kidney International · 2022 · https://doi.org/10.1016/j.kint.2022.06.008

• Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)02074-8

• 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

  European Heart Journal · 2021 · https://doi.org/10.1093/eurheartj/ehab484

• Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney

  Clinical Kidney Journal · 2021 · https://doi.org/10.1093/ckj/sfab070

• Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2022190

• Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

  Kidney International · 2020 · https://doi.org/10.1016/j.kint.2020.09.006

• Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

  The Lancet · 2019 · 10.1016/s0140-6736(18)31942-1

• Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

  JAMA · 2018 · 10.1001/jama.2018.18269

• Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology

  European Heart Journal · 2018 · https://doi.org/10.1093/eurheartj/ehy596

• Chronic kidney disease

  Nature Reviews Disease Primers · 2017 · 10.1038/nrdp.2017.88

• How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

  Diabetes Care · 2017 · 10.2337/dc17-1096

• Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial

  European Heart Journal · 2016 · 10.1093/eurheartj/ehv728

• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1515920

• Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

  Kidney International · 2016 · 10.1016/j.kint.2015.10.002

• CKD Prevalence Varies across the European General Population

  Journal of the American Society of Nephrology · 2015 · 10.1681/asn.2015050542

• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1504720

• KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient

  Kidney International · 2014 · 10.1038/ki.2014.31

• Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry

  Nephrology Dialysis Transplantation · 2014 · https://doi.org/10.1093/ndt/gfu017

• Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism

  Kidney International · 2013 · 10.1038/ki.2013.147

• Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1306033

• Etiology of the Protein-Energy Wasting Syndrome in Chronic Kidney Disease: A Consensus Statement From the International Society of Renal Nutrition and Metabolism (ISRNM)

  Journal of Renal Nutrition · 2013 · 10.1053/j.jrn.2013.01.001

• Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease

  JAMA · 2012 · https://doi.org/10.1001/jama.2012.120

• A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease

  Kidney International · 2007 · 10.1038/sj.ki.5002585

• Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis

  New England Journal of Medicine · 2005 · 10.1056/nejmoa043545

• Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study

  The Lancet · 2003 · 10.1016/s0140-6736(03)12710-9

• Review on uremic toxins: Classification, concentration, and interindividual variability

  Kidney International · 2003 · 10.1046/j.1523-1755.2003.00924.x

• Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

  Kidney International · 1999 · 10.1046/j.1523-1755.1999.00273.x

Current projects

No projects listed.